Akebia Therapeutics initiates Phase 2 trial of praliciguat for FSGS
Akebia Therapeutics is conducting Phase 2 trial to assess praliciguat's efficacy and safety in FSGS patients.
Asset / Drug
Drug and asset intelligence for Akebia with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.